Products from TargetMol
TargetMol, based in Boston, Massachusetts, was founded in 2015 and is a drug screening expert in the life science community. The company offers diverse compound libraries, including FDA-approved libraries, and covers a broad spectrum of small molecule compounds such as inhibitors and agonists as well as recombinant proteins and natural products. TargetMol's products are used by researchers worldwide in areas such as cancer research, neurobiology, inflammation, immunology and metabolism.
More information at: www.targetmol.com
No results were found for the filter!
Crotedumab
Item number: TGM-T76862-5mg
Description: Crotedumab (REGN1193), a fully human IgG4 monoclonal antibody, selectively binds to and inhibits the glucagon receptor (GCGR) with a dissociation constant (K D) of 0.1 nM, making it a potent candidate for diabetes research [1] [2].
| Application: | Targets glucagon receptor (GCGR) |
| CAS | 1452387-69-7 |
487.00€
*
Enapotamab
Item number: TGM-T76864-10mg
Description: Enapotamab is an AXL/UFO-related antibody that can be used to synthesize antibody-drug couplings (Enapotamab Vedotin). Target: TAM Receptor. References: Matthew T. Burger, et al. Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof. WO2022115477A1.
From 215.00€
*
Enavatuzumab
Item number: TGM-T76865-5mg
Description: Enavatuzumab (PDL192, ABT-361) is a humanized IgG1 monoclonal antibody targeting the TWEAK receptor (TweakR), a protein involved in various cellular responses through its interaction with TWEAK (Fn14, TNFRSF12A). By engaging TweakR signaling and promoting antibody-dependent cell-mediated cytotoxicity...
588.00€
*
Ravulizumab
Item number: TGM-T76867-100mg
Description: Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds to human complement protein C5 with high affinity, targeting complement factor 5 to block complement activation. It can be used for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, atypical hemolytic...
| Keywords: | ALXN1210 |
| Application: | Targets complement component 5 (C5) |
| CAS | 1803171-55-2 |
From 233.00€
*
Lacnotuzumab
Item number: TGM-T76868-5mg
Description: Lacnotuzumab (MCS110), a humanized IgG1/kappa monoclonal antibody, neutralizes and inhibits the interaction between CSF-1 and its receptor, CSF-1R. It is utilized in researching pigmented villonodular synovitis [1] [2].
1,099.00€
*
Lirentelimab
Item number: TGM-T76869-5mg
Description: Lirentelimab (AK002), a humanized IgG1 monoclonal antibody, specifically targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). It promotes apoptosis in IL-5-activated eosinophils and suppresses IgE-mediated activation of mast cells. This compound is under investigation for the treatment of...
| Application: | Targets sialic acid binding Ig-like lectin 8 (SIGLEC8) |
| CAS | 2283348-97-8 |
487.00€
*
Narsoplimab
Item number: TGM-T76870-10mg
Description: Narsoplimab (OMS 721) is a selective whole-human immunoglobulin gamma-4 (IgG4) monoclonal antibody and a mannan-binding lectin-associated serine protease-2 (MASP-2) inhibitor that binds MASP-2 to prevent lectin pathway activation and inhibit the agglutinin pathway. It is used to study diseases...
| Keywords: | OMS 721 |
From 248.00€
*
Navicixizumab
Item number: TGM-T76871-5mg
Description: Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody that can be combined with Paclitaxel for cancer research, particularly in studies of ovarian, primary peritoneal, or fallopian tube cancer [1] [2] [3].
| Application: | Targets delta (DLL) |
| CAS | 1638338-43-8 |
Please request pricing for this article.
Neihulizumab
Item number: TGM-T76872-5mg
Description: Neihulizumab (ALTB-168), an immune checkpoint agonistic antibody, targets and binds to human CD162 (PSGL-1), resulting in the downregulation of activated T-cells. It is utilized in research aimed at treating steroid-refractory acute graft-versus-host disease (SR-aGVHD), psoriasis, psoriatic arthritis,...
| CAS | 2158362-38-8 |
705.00€
*
Nidanilimab
Item number: TGM-T76873-10mg
Description: Nidanilimab (CAN04) is a fully humanized IL1RAP monoclonal antibody with a Kd value of 1.10 pM. It exhibits antitumor activity by disrupting the IL1alpha and IL1beta signaling pathways and inducing the immune system to destroy tumor cells. Nidanilimab can be used to study solid cancers, such as...
| Keywords: | CAN04 |
| CAS | 2171061-85-9 |
From 229.00€
*
Erenumab
Item number: TGM-T76874-10mg
Description: Erenumab is a whole-human monoclonal antibody. Erenumab inhibits calcitonin gene-related peptide (CGRP) receptors. Erenumab can be used to prevent migraine attacks. Target: CGRP Receptor. References: Goadsby PJ, Reuter U, Hallström Y, et al. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J...
| Keywords: | AMG-334 |
From 200.00€
*
Zanidatamab
Item number: TGM-T76875-5mg
Description: Zanidatamab (ZW25) is a bispecific, humanized monoclonal antibody that targets two distinct epitopes (ECD2 and ECD4) of the HER2 receptor, exhibiting anti-tumor activity [1].
| Application: | Targets receptor tyrosine-protein kinase erbB-2 [EC:2.7.10.1] (ERBB2, HER2, CD340) |
| CAS | 2169946-15-8 |
887.00€
*